Hypercoagulable Atrial Appendages in atrial fibrillation (AF): a cross sectional pilot study

Completed

• Conditions: atrial fibrillation; 10007521; 10014523

• Registration Number: NL-OMON31424
• Lead Sponsor: Academisch Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

Inclusion criteria cases
1. Electrocardiographically established diagnosis of atrial fibrillation
2. Need for thoracic surgery (requiring median sternotomy);Inclusion criteria controls
1. 18 years or older
2. Need for thoracic surgery (requiring median sternotomy)

Exclusion Criteria

Exclusion criteria cases
1. No written informed consent
2. Age under 18 years
3. Severe mitral or aortic valve disease
4. Secondary AF
5. Kidney dysfunction (GFR <30 ml/min, estimated by the Cockroft-Gault formula)
6. Use of experimental study medication in past 6 months;Exclusion criteria controls
1. Electrocardiographically established diagnosis of atrial fibrillation
2. Severe mitral or aortic valve disease
3. No written informed consent
4. Kidney dysfunction (GFR <30 ml/min, estimated by the Cockroft-Gault formula)
5. Use of experimental study medication in past 6 months

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Degree of TM an TF expression and activity in the atrial appendages<br /><br>Degree of CML-CEL expression in the atrial appendages</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Serum CML-CEL values<br /><br>Skin auto fluorescence values of AGEs<br /><br>Viral presence in atrial appendages<br /><br>Atrial appendage proteomics<br /><br>AF score (representing the electrophysiological tissue properties)</p><br>